Chemotherapy of leishmaniasis. Part XI: Synthesis and bioevaluation of novel isoxazole containing heteroretinoid and its amide derivatives

Bioorganic & Medicinal Chemistry Letters
2012.0

Abstract

Novel isoxazole containing heteroretinoid (4) and its amide derivatives (5a-j) have been synthesized and evaluated for their in vivo antileishmanial activity against Leishmania donovani in hamsters. Compounds 3, 5a, 5d, 5k and 5l inhibited 70-76% parasite growth at 50 mg kg(-1) ×5 days. The present study has helped us in identifying a new lead that could be exploited as a potential antileishmanial agent.

Knowledge Graph

Similar Paper

Chemotherapy of leishmaniasis. Part XI: Synthesis and bioevaluation of novel isoxazole containing heteroretinoid and its amide derivatives
Bioorganic & Medicinal Chemistry Letters 2012.0
Chemotherapy of leishmaniasis. Part XII: Design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents
Bioorganic & Medicinal Chemistry Letters 2013.0
Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as antileishmanial agents
Bioorganic & Medicinal Chemistry Letters 2010.0
Synthesis and evaluation of monoamidoxime derivatives: Toward new antileishmanial compounds
European Journal of Medicinal Chemistry 2011.0
Synthesis and evaluation of original amidoximes as antileishmanial agents
Bioorganic & Medicinal Chemistry 2010.0
Synthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs, and evaluation of biological activity against Leishmania donovani
MedChemComm 2015.0
Design and synthesis of novel tetrahydronaphthyl azoles and related cyclohexyl azoles as antileishmanial agents
Bioorganic & Medicinal Chemistry Letters 2011.0
Synthesis and evaluation of new furanyl and thiophenyl azoles as antileishmanial agents
European Journal of Medicinal Chemistry 2011.0
Aryloxy cyclohexyl imidazoles: A novel class of antileishmanial agents
Bioorganic & Medicinal Chemistry Letters 2009.0
Synthesis and antileishmanial evaluation of 1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazole derivatives
Bioorganic & Medicinal Chemistry Letters 2011.0